Custom Report

La Merie Publishing offers the service of preparing customized reports tailored to the needs and specifications of the customer. We conduct scientific & medical literature evaluations for clients of the biopharmaceutical industry within the scope of our expertise. Target or technology pipeline and corporate benchmark analysis and assessment reports can be prepared according to the specifications of the client from the pharmaceutical or biotechnology industry.

More info

Merck Serono announced today that a phase II trial investigating the humanized monoclonal antibody matuzumab in combination with irinotecan in patients with metastatic colorectal cancer has not met its predefined endpoint of activity

DARMSTADT, Germany | August 29, 2007 | Merck Serono, a division of Merck KGaA, announced today that a phase II trial investigating the humanized monoclonal antibody matuzumab in combination with irinotecan in patients with metastatic colorectal cancer (mCRC) who had already failed on multiple prior treatments, including irinotecan, has not met its predefined endpoint of activity. Merck Serono is therefore reconsidering further development of matuzumab in mCRC at this stage.

Matuzumab is currently being co-developed and co-commercialized via a partnership between Merck Serono and Takeda. Both companies share the view that the study results in mCRC do not meet expectations. The companies are, however, continuing to study the drug in other tumors including non-small cell lung cancer (NSCLC).
More than 370,000 people develop colorectal cancer in Europe every year, accounting for 13% of the total cancer burden and around 200,000 deaths.1 Approximately 25% of patients present with metastatic disease.2 Five-year survival rates for patients with mCRC are as low as 5%.3

References:

1. Parkin DM et al. CA Cancer J Clin 2005; 55: 72-108
2. GLOBOCAN. http://www-dep.iarc.fr/
3. Argiris A et al. Cancer 2004; 101: 2222-2229

SOURCE: MERCK

Post Views: 154